Swiftly Meds Private Limited

Adthal 100 mg capsules contain Adapalene, which is a topical retinoid primarily used for the treatment of acne. It works by regulating skin cell turnover, preventing pores from becoming clogged, and reducing inflammation. Adthal capsules are often prescribed for moderate to severe acne, and they help to clear up acne lesions and prevent future breakouts. It is important to follow the prescribed dosage and use guidelines, as excessive use can lead to skin irritation or other side effects. Always consult with a healthcare provider for proper guidance.

Celomide 10 mg Capsule – Description

Brand Name: Celomide
Generic Name: Mycophenolate Mofetil
Strength: 10 mg
Dosage Form: Capsule

Overview: Celomide 10 mg capsule is a prescription medication primarily used as an immunosuppressant to prevent the rejection of organ transplants, particularly kidney, heart, or liver transplants. The active ingredient in Celomide is mycophenolate mofetil, which works by inhibiting the activity of certain immune system cells that could attack a transplanted organ. This medication is also used in the treatment of autoimmune disorders such as lupus nephritis and other conditions where the immune system is overactive.

Indications:

1. Organ Transplantation: Celomide is used in combination with other immunosuppressive drugs (such as corticosteroids) to prevent organ rejection in kidney, liver, or heart transplant patients.
2. Autoimmune Diseases: It is also prescribed to manage certain autoimmune diseases like lupus nephritis, where the immune system attacks the body’s own tissues, causing kidney damage.
3. Other Conditions: Celomide may be indicated for other conditions as determined by a healthcare provider, where immune system suppression is necessary.

Dosage:

• Recommended Dosage: The typical dosage of Celomide is 10 mg per capsule, although the dosage may vary based on the individual’s specific condition, transplant type, and medical history.
• The exact dosage and duration of treatment will be determined by the doctor. It is important to follow the prescribed dosing schedule for the best results.
• For transplant recipients, the usual dose may be adjusted based on the severity of the transplant rejection or other factors.
• Administration: Celomide capsules should be taken orally with or without food. Swallow the capsule whole with a glass of water. Do not crush, chew, or break the capsule.

Side Effects: Like all medications, Celomide can cause side effects, although not everyone will experience them. Common side effects include:

• Nausea, vomiting, or diarrhea
• Headaches
• Fatigue or weakness
• Increased risk of infection (due to immune suppression)
• High blood pressure
• Low white blood cell count (leukopenia)

Severe side effects may include:

• Severe infections (due to immune system suppression)
• Gastrointestinal bleeding
• Liver damage (hepatotoxicity)
• Severe allergic reactions (rash, swelling, breathing difficulties)

Patients should seek medical attention if they experience unusual symptoms such as signs of infection, severe abdominal pain, or persistent bruising or bleeding.

Precautions:

• Pregnancy and Breastfeeding: Celomide is contraindicated during pregnancy due to its teratogenic effects (it can cause harm to the fetus). Women who are pregnant or planning to become pregnant should not take Celomide. It is also not recommended during breastfeeding.
• Infections: Celomide suppresses the immune system, making it easier to contract infections. Patients should be vigilant about infection risks and report any signs of illness to their doctor.
• Regular Monitoring: While on Celomide, patients will require regular blood tests to monitor blood cell counts, liver function, and kidney function.

Storage: Store Celomide capsules at room temperature (between 20°C and 25°C or 68°F and 77°F), away from moisture and heat. Keep the capsules in their original packaging to protect them from light and humidity.

Bortirel 3.5 mg Injection - Description

Generic Name: Bortezomib
Brand Name: Bortirel
Strength: 3.5 mg per vial
Form: Injection (intravenous or subcutaneous)

Indication:
Bortirel 3.5 mg Injection, containing bortezomib as the active ingredient, is primarily used in the treatment of multiple myeloma (a type of blood cancer) and mantle cell lymphoma (a rare form of non-Hodgkin lymphoma). It is typically used in patients who have not previously received therapy or those who have relapsed after initial treatment.

Mechanism of Action:
Bortezomib is a proteasome inhibitor that works by blocking the activity of the proteasome, an enzyme complex responsible for degrading unwanted or misfolded proteins in cells. By inhibiting this process, bortezomib causes the accumulation of these proteins, which leads to cell death, particularly in cancerous cells. This action is particularly effective against rapidly dividing cancer cells, making Bortirel a crucial therapy for certain hematologic malignancies.

Dosage and Administration:

• Multiple Myeloma: The typical dosing regimen is 1.3 mg/m² of body surface area, administered intravenously or subcutaneously. The treatment is usually given twice a week for two weeks, followed by a 10-day rest period.
• Mantle Cell Lymphoma: The recommended dose is similar, and treatment schedules are adjusted based on the patient's response and tolerability.

Treatment cycles may vary, and the healthcare provider will determine the exact dosage schedule depending on individual patient factors, including response to the drug and any side effects experienced.

Contraindications:
Bortirel is contraindicated in patients who are hypersensitive to bortezomib or any component of the injection. It should not be used in patients with severe thrombocytopenia (low platelet count) or neutropenia (low white blood cell count) unless the benefits outweigh the risks.

Precautions and Warnings:

• Hematologic Effects: Bortirel can cause severe thrombocytopenia and neutropenia, which may lead to an increased risk of bleeding or infection. Regular blood tests should be conducted to monitor blood cell counts.
• Peripheral Neuropathy: Patients may experience symptoms of peripheral neuropathy, including tingling, numbness, or pain in the hands and feet. Dose adjustments may be necessary based on severity.
• Cardiac Events: Patients with pre-existing heart conditions may be at higher risk for cardiac events, such as heart failure.
• Pregnancy and Lactation: Bortezomib is classified as a Category D drug (positive evidence of risk) during pregnancy and should not be used during pregnancy unless absolutely necessary. It is also not recommended during breastfeeding.

Side Effects:
Common side effects of Bortirel include:

• Nausea and vomiting
• Fatigue
• Diarrhea or constipation
• Peripheral neuropathy (numbness, tingling, or pain in extremities)
• Low blood counts (e.g., thrombocytopenia, neutropenia)
• Fever
• Dehydration

Serious side effects may include heart problems, liver toxicity, and severe infections. Patients should immediately report any signs of unusual bleeding, infection, or heart problems to their healthcare provider.

Storage:
Bortirel should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). It must not be frozen, and any unused medication should be disposed of in accordance with local regulations.